Jorge A Zamora-Legoff1, Megan L Krause1, Cynthia S Crowson1,2, Jay H Ryu3, Eric L Matteson1,4. 1. Division of Rheumatology. 2. Division of Biomedical Statistics and Informatics, Department of Health Sciences Research. 3. Division of Pulmonary and Critical Care Medicine. 4. Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, MN, USA.
Abstract
Objective: To characterize a cohort of patients with RA who have interstitial lung disease (ILD) and to assess the utility of previously developed mortality staging systems [gender, age, lung physiology (GAP) and ILD-GAP]. Methods: All patients with RA and ILD seen at the Mayo Clinic from 1998 to 2014 were identified and manually screened for study inclusion. RA disease characteristics and pulmonary findings including high-resolution CT and pulmonary function testing were evaluated. Survival was estimated using Kaplan-Meier methods. GAP and ILD-GAP models were evaluated using c-statistics and standardized incidence ratios. Results: The study included 181 patients with RA-associated ILD (96% Caucasian; 48% females; 37% never-smokers). The mean age at ILD diagnosis was 67.4 years ( s . d . 9.9). The median time from RA diagnosis to ILD was 4.9 years (range -10.9-48.1). The median follow-up was 3.1 years (range 0.01-14.8). Age, RA disease duration and low initial diffusing capacity for carbon monoxide were predictive of premature mortality in multivariate modelling. Sex, smoking status, obstructive lung disease, seropositivity and erosive disease were not associated with mortality. The 5-year survival rate was 59.7% (95% CI 51.5, 69.2). Survival did not differ between usual interstitial pneumonia, non-specific interstitial pneumonia and organizing pneumonia ( P = 0.42). The GAP model performed well in this cohort for both discrimination and calibration (c-statistic 0.71, standardized incidence ratio 0.97). Conclusion: In this large single-centre cohort of patients with RA-ILD, most patients were seropositive and had a history of smoking. ILD most commonly occurred after the RA diagnosis. Mortality was high and did not differ among the types. The GAP model may be useful in assessing mortality risk.
Objective: To characterize a cohort of patients with RA who have interstitial lung disease (ILD) and to assess the utility of previously developed mortality staging systems [gender, age, lung physiology (GAP) and ILD-GAP]. Methods: All patients with RA and ILD seen at the Mayo Clinic from 1998 to 2014 were identified and manually screened for study inclusion. RA disease characteristics and pulmonary findings including high-resolution CT and pulmonary function testing were evaluated. Survival was estimated using Kaplan-Meier methods. GAP and ILD-GAP models were evaluated using c-statistics and standardized incidence ratios. Results: The study included 181 patients with RA-associated ILD (96% Caucasian; 48% females; 37% never-smokers). The mean age at ILD diagnosis was 67.4 years ( s . d . 9.9). The median time from RA diagnosis to ILD was 4.9 years (range -10.9-48.1). The median follow-up was 3.1 years (range 0.01-14.8). Age, RA disease duration and low initial diffusing capacity for carbon monoxide were predictive of premature mortality in multivariate modelling. Sex, smoking status, obstructive lung disease, seropositivity and erosive disease were not associated with mortality. The 5-year survival rate was 59.7% (95% CI 51.5, 69.2). Survival did not differ between usual interstitial pneumonia, non-specific interstitial pneumonia and organizing pneumonia ( P = 0.42). The GAP model performed well in this cohort for both discrimination and calibration (c-statistic 0.71, standardized incidence ratio 0.97). Conclusion: In this large single-centre cohort of patients with RA-ILD, most patients were seropositive and had a history of smoking. ILD most commonly occurred after the RA diagnosis. Mortality was high and did not differ among the types. The GAP model may be useful in assessing mortality risk.
Authors: Deborah Assayag; Brett M Elicker; Thomas H Urbania; Thomas V Colby; Bo Hyoung Kang; Jay H Ryu; Talmadge E King; Harold R Collard; Dong Soon Kim; Joyce S Lee Journal: Radiology Date: 2013-10-28 Impact factor: 11.105
Authors: Tim Bongartz; Carlotta Nannini; Yimy F Medina-Velasquez; Sara J Achenbach; Cynthia S Crowson; Jay H Ryu; Robert Vassallo; Sherine E Gabriel; Eric L Matteson Journal: Arthritis Rheum Date: 2010-06
Authors: Christopher J Ryerson; Eric Vittinghoff; Brett Ley; Joyce S Lee; Joshua J Mooney; Kirk D Jones; Brett M Elicker; Paul J Wolters; Laura L Koth; Talmadge E King; Harold R Collard Journal: Chest Date: 2014-04 Impact factor: 9.410
Authors: E J Kim; B M Elicker; F Maldonado; W R Webb; J H Ryu; J H Van Uden; J S Lee; T E King; H R Collard Journal: Eur Respir J Date: 2009-12-08 Impact factor: 16.671
Authors: Brett Ley; Christopher J Ryerson; Eric Vittinghoff; Jay H Ryu; Sara Tomassetti; Joyce S Lee; Venerino Poletti; Matteo Buccioli; Brett M Elicker; Kirk D Jones; Talmadge E King; Harold R Collard Journal: Ann Intern Med Date: 2012-05-15 Impact factor: 25.391
Authors: Joshua J Solomon; Jonathan H Chung; Gregory P Cosgrove; M Kristen Demoruelle; Evans R Fernandez-Perez; Aryeh Fischer; Stephen K Frankel; Stephen B Hobbs; Tristan J Huie; Jill Ketzer; Amar Mannina; Amy L Olson; Gloria Russell; Yutaka Tsuchiya; Zulma X Yunt; Pearlanne T Zelarney; Kevin K Brown; Jeffrey J Swigris Journal: Eur Respir J Date: 2015-11-19 Impact factor: 16.671
Authors: Emily K Wu; Robert D Ambrosini; R Matthew Kottmann; Christopher T Ritchlin; Edward M Schwarz; Homaira Rahimi Journal: Curr Rheumatol Rev Date: 2019
Authors: Ayodeji Adegunsoye; Justin M Oldham; Shashi K Bellam; Jonathan H Chung; Paul A Chung; Kathleen M Biblowitz; Steven Montner; Cathryn Lee; Scully Hsu; Aliya N Husain; Rekha Vij; Gokhan Mutlu; Imre Noth; Matthew M Churpek; Mary E Strek Journal: Eur Respir J Date: 2018-06-14 Impact factor: 16.671
Authors: Sicong Huang; Tracy J Doyle; Mark M Hammer; Suzanne C Byrne; Weixing Huang; Allison A Marshall; Christine K Iannaccone; Jie Huang; Vivi Feathers; Michael E Weinblatt; Paul F Dellaripa; Nancy A Shadick; Jeffrey A Sparks Journal: Semin Arthritis Rheum Date: 2020-09-28 Impact factor: 5.532
Authors: Emily K Wu; Zoe I Henkes; Brion McGowan; Richard D Bell; Moises J Velez; Alexandra M Livingstone; Christopher T Ritchlin; Edward M Schwarz; Homaira Rahimi Journal: J Immunol Date: 2019-10-28 Impact factor: 5.422